1105. Statewide, Retrospective, Cohort Study of Medicare Part B Quinolone Prescribing for Cystitis in 2016–2017
Abstract
Abstract Background Quinolones (FQ) are no longer recommended as first-line therapy for cystitis. In 2016, the FDA released a safety communication advising FQ restriction in the treatment of uncomplicated urinary tract infection unless no other options are available. However, little is known about the frequency of FQ (FFQ) prescribing in older adults (OA) receiving antibiotics for cystitis in New York State (NYS). This study compared the FFQ prescribing in OA receiving antibiotics with a diagnosis of cystitis in NYS between 2016 and 2017. Methods Retrospective, cohort study of (NYS) Part B Medicare fee-for-service beneficiaries in 2016 and 2017 with diagnosis codes for cystitis. All antibiotics prescribed ≤ 3 days after visit were analyzed. FQ were defined as ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin. County-wide data were aggregated into regional data per NYS Department of Health Population Health Improvement Program categories, but New York City counties were not grouped. FFQ was analyzed at the state and regional level and was defined as the total # of FQ prescriptions / total # of antibiotic prescriptions with the diagnostic code for cystitis. χ 2 test and Risk Ratios (RR = 2017 FFQ/2016 FFQ) were used to compare 2016 and 2017 FFQs for the state and for each region using SAS v 9.3 (α = 0.05). Results 50,658 antibiotic prescriptions were written for Medicare beneficiaries diagnosed with cystitis in NYS. The statewide FFQ decreased by…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.